Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | CFTR | P13569 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4577459 | 0.86 | ALDH1A1 (0.43) | ALDH1A1HSD17B10KDM4EHIF1ATDP1 | |
| SCHEMBL9340040 | 0.86 | ALDH1A1 (0.53) | ALDH1A1HSD17B10KDM4EHIF1ATDP1 | |
| SCHEMBL30852342 | 0.86 | ALDH1A1 (0.53) | ALDH1A1HSD17B10KDM4EHIF1ATDP1 | |
| SCHEMBL25665243 | 0.86 | ALDH1A1 (0.53) | ALDH1A1HSD17B10KDM4EHIF1ATDP1 | |
| SCHEMBL30852281 | 0.84 | ALDH1A1 (0.59) | ALDH1A1HSD17B10KDM4EHIF1ATDP1 | |
| Kynurenine SCHEMBL288988 | 0.81 | KDM4E (0.64) | ALDH1A1HSD17B10KDM4EHIF1ATDP1 | |
| Kynurenine SCHEMBL2181581 | 0.81 | KDM4E (0.64) | ALDH1A1HSD17B10KDM4EHIF1ATDP1 | |
| L-Kynurenine SCHEMBL13969610 | 0.81 | KDM4E (0.64) | ALDH1A1HSD17B10KDM4EHIF1ATDP1 | |
| L-Kynurenine SCHEMBL288989 | 0.81 | KDM4E (0.64) | ALDH1A1HSD17B10KDM4EHIF1ATDP1 | |
| Kynurenine SCHEMBL20874 | 0.81 | KDM4E (0.64) | ALDH1A1HSD17B10KDM4EHIF1ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111239880-B | Apparatus for evaluating and selecting filters for minimizing glare and color vision loss | 詹姆斯·M·加拉斯 | 2022-06-14 | — | — | CN | claimed |
| WO-2026102332-A1 | NERVE AND TUMOR HOMING AGENTS AND METHODS OF USE THEREOF | Blaze Bioscience, Inc. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20250367269-A1 | KYNURENINE AMINOTRANSFERASE AND PRODUCTS THEREOF FOR THE TREATMENT OF ARTHRITIC DISEASES | INSTITUT NATIONAL DE RECH POUR LAGRICULTURE LALIMENTATION ET L’ENVIRONNEMENT (FR) | 2025-12-04 | — | — | US | disclosed |
| US-20250027949-A1 | EVALUATING METHOD FOR RELATIVE PHARMACOLOGICAL ACTIONS OF COMBINATIONS OF IMMUNE CHECKPOINT INHIBITORS AND ANTICANCER DRUGS AS COMBINATION DRUGS COMPARED WITH PHARMACOLOGICAL ACTIONS OF IMMUNE CHECKPOINT INHIBITORS ALONE, CALCULATING METHOD, EVALUATING APPARATUS, CALCULATING APPARATUS, EVALUATING PROGRAM, CALCULATING PROGRAM, RECORDING MEDIUM, EVALUATING SYSTEM, AND TERMINAL APPARATUS | AJINOMOTO CO., INC. (JP) | 2025-01-23 | — | — | US | disclosed |
| WO-2023247415-A1 | KYNURENINE AMINOTRANSFERASE AND PRODUCTS THEREOF FOR THE TREATMENT OF ARTHRITIC DISEASES | INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT (FR) | 2023-12-28 | — | — | WO | disclosed |
| EP-4295859-A1 | KYNURENINE AMINOTRANSFERASE AND PRODUCTS THEREOF FOR THE TREATMENT OF ARTHRITIC DISEASES | Institut national de recherche pour l'agriculture, l'alimentation et l'environnement (FR) | 2023-12-27 | — | — | EP | disclosed |
| WO-2023195447-A1 | EVALUATION METHOD, CALCULATION METHOD, EVALUATION DEVICE, CALCULATION DEVICE, EVALUATION PROGRAM, CALCULATION PROGRAM, RECORDING MEDIUM, EVALUATION SYSTEM AND TERMINAL DEVICE FOR RELATIVE PHARMACOLOGICAL ACTION OF COMBINATION OF IMMUNE CHECKPOINT INHIBITOR WITH ANTICANCER DRUG AS CONCOMITANT DRUG COMPARED TO PHARMACOLOGICAL ACTION OF IMMUNE CHECKPOINT INHIBITOR ALONE | 味の素株式会社 | 2023-10-12 | — | — | WO | disclosed |
| EP-4251157-A1 | NICOTINAMIDE, NICOTINAMIDE PRECURSORS AND NICOTINAMIDE METABOLITES AND COMPOSITIONS THEREOF FOR REDUCING THE TIME TO RESOLUTION OF SYMPTOMS IN PATIENTS WITH COVID-19 AND OTHER VIRAL INFECTIONS | CONARIS research institute AG (DE) | 2023-10-04 | — | — | EP | disclosed |
| US-20220268790-A1 | EVALUATING METHOD FOR PHARMACOLOGICAL ACTIONS OF IMMUNE CHECKPOINT INHIBITORS, CALCULATING METHOD, EVALUATING APPARATUS, CALCULATING APPARATUS, EVALUATING PROGRAM, CALCULATING PROGRAM, RECORDING MEDIUM, EVALUATING SYSTEM, AND TERMINAL APPARATUS | AJINOMOTO CO., INC. (JP) | 2022-08-25 | — | — | US | disclosed |
| US-20220229077-A1 | DIAGNOSIS, PROGNOSIS AND TREATMENT FOR SCHIZOPHRENIA AND SCHIZOAFFECTIVE PSYCHOSIS | PRECISION MEDICINE HOLDINGS PTY LTD (AU) | 2022-07-21 | — | — | US | disclosed |
| EP-2869719-A1 | PRODUCT FOR USE IN THE PROPHYLACTIC OR THERAPEUTIC TREATMENT OF A NEGATIVE EMOTION OR INTROVERT BEHAVIOUR | N.V. Nutricia (NL) | 2015-05-13 | — | — | EP | disclosed |
| EP-2869718-A1 | DIETARY FIBRE FOR USE IN THE TREATMENT OF A GASTRO-INTESTINAL SIDE-EFFECT OF A NUTRITION OR MEDICAMENT | N.V. Nutricia (NL) | 2015-05-13 | — | — | EP | disclosed |
| US-20140139803-A1 | Ophthalmic lenses with melanin and ocular lens pigment having low fluorescence | PHOTOPROTECTIVE TECHNOLOGIES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| WO-2014007636-A1 | PRODUCT FOR USE IN THE PROPHYLACTIC OR THERAPEUTIC TREATMENT OF A NEGATIVE EMOTION OR INTROVERT BEHAVIOUR | N.V. NUTRICIA (NL) | 2014-01-09 | — | — | WO | disclosed |
| WO-2014007635-A1 | DIETARY FIBRE FOR USE IN THE TREATMENT OF A GASTRO-INTESTINAL SIDE-EFFECT OF A NUTRITION OR MEDICAMENT | N.V. NUTRICIA (NL) | 2014-01-09 | — | — | WO | disclosed |
| WO-2014007606-A1 | PRODUCT FOR USE IN THE PROPHYLACTIC OR THERAPEUTIC TREATMENT OF A NEGATIVE EMOTION OR INTROVERT BEHAVIOUR | N.V. NUTRICIA (NL) | 2014-01-09 | — | — | WO | disclosed |
| WO-2009063241-A1 | 3-HYDROXYANTHRANILIC ACID OR SALTS THEREOF1 FOR TREATING CANCER OR INFECTIONS | LUDWIG INSTITUT FUR KREBSFORSCHUNG AG (US) | 2009-05-22 | — | — | WO | disclosed |
| EP-1601799-A4 | METHODS AND COMPOSITIONS FOR TREATING AIDS AND HIV-RELATED DISORDERS USING 9145, 1725, 311, 837, 58305, 156, 14175, 50352, 32678, 5560, 7240, 8865, 12396, 12397, 13644, 19938, 2077, 1735, 1786, 10220, 17822, 33945, 43748, 47161, 81982, OR 46777 | MILLENNIUM PHARM INC (US) | 2007-06-06 | — | — | EP | disclosed |
| EP-1601799-A2 | METHODS AND COMPOSITIONS FOR TREATING AIDS AND HIV-RELATED DISORDERS USING 9145, 1725, 311, 837, 58305, 156, 14175, 50352, 32678, 5560, 7240, 8865, 12396, 12397, 13644, 19938, 2077, 1735, 1786, 10220, 17822, 33945, 43748, 47161, 81982, OR 46777 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-12-07 | — | — | EP | disclosed |
| WO-2004080535-A2 | METHODS AND COMPOSITIONS FOR TREATING AIDS AND HIV-RELATED DISORDERS USING 9145, 1725, 311, 837, 58305, 156, 14175, 50352, 32678, 5560, 7240, 8865, 12396, 12397, 13644, 19938, 2077, 1735, 1786, 10220, 17822, 33945, 43748, 47161, 81982, OR 46777 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250367269-A1 | KYNURENINE AMINOTRANSFERASE AND PRODUCTS THEREOF FOR THE TREATMENT OF ARTHRITIC DISEASES | AADAT, KYNU, KMO | ALDH1A1 1153/4885HSD17B10 283/4885KDM4E 1825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.